Hypoxia-inducible MIR-182 enhances HIF1α signaling via targeting PHD2 and FIH1 in prostate cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Yan ^a   Zhang, Duo ^a   Wang, Xiaoyun ^a   Yao, Xuan ^a   Ye, Cheng ^a   Zhang, Shengjie ^a   Wang, Hui ^a   Chang, Cunjie ^b   Xia, Hongfeng ^a   Wang, Yu Cheng ^c,d   Fang, Jing ^a,e   Yan, Jun ^b   Ying, Hao ^a,d,e  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b NANJING UNIVERSITY   (China)

^c Shanghai Xuhui Central Hospital   (China)

^d Chinese Academy of Sciences   (China)

^e BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EGLN1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HIF1AN PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; MICRORNA; MIRN182 MICRORNA, HUMAN; MIXED FUNCTION OXIDASE; REPRESSOR PROTEIN; RNA; TUMOR PROTEIN;

ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL HYPOXIA; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; HETEROGRAFTS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MICE; MICE, KNOCKOUT; MICRORNAS; MIXED FUNCTION OXYGENASES; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 84937892977     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12495     Document Type: Article

References (41)

1. Bertout, J. A., Patel, S. A. & Simon, M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8, 967-975 (2008).
2. Denko, N. C. et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22, 5907-5914 (2003).
3. Hockel, M. & Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276 (2001).
4. Nanni, S. et al. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J. Clin. Invest. 119, 1093-1108 (2009).
5. Movsas, B. et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 89, 2018-2024 (2000).
6. Bostwick, D. G. & Iczkowski, K. A. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin. Urol. Oncol. 16, 118-123 (1998).
7. Pallares, J. et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol. Histopathol. 21, 857-865 (2006).
8. Marignol, L., Coffey, M., Lawler, M. & Hollywood, D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat. Rev. 34, 313-327 (2008).
9. Semenza, G. L. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci. STKE. 2007, cm8 (2007).
10. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
11. Mahon, P. C., Hirota, K. & Semenza, G. L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686 (2001).
12. Metzen, E. et al. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J. 387, 711-717 (2005).
13. Bardos, J. I. & Ashcroft, M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26, 262-269 (2004).
14. Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857-866 (2005).
15. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
16. Zhong, H. et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59, 5830-5835 (1999).
17. Zhong, H., Semenza, G. L., Simons, J. W. & De Marzo, A. M. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev. 28, 88-93 (2004).
18. Ranasinghe, W. K. et al. The effects of nonspecific HIF1alpha inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med. 3, 245-251 (2014).
19. Stefani, G. & Slack, F. J. Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell Biol. 9, 219-230 (2008).
20. Huang, X. et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell 35, 856-867 (2009).
21. Kelly, T. J., Souza, A. L., Clish, C. B. & Puigserver, P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol. Cell. Biol. 31, 2696-2706 (2011).
22. Wang, H. et al. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat. Immunol. 15, 393-401 (2014).
23. Liu, C. J. et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 70, 1635-1644 (2010).
24. Ghosh, G. et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J. Clin. Invest. 120, 4141-4154 (2010).
25. Chen, Z. et al. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J. Clin. Invest. 123, 1057-1067 (2013).
26. Schaefer, A. et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126, 1166-1176 (2010).
27. Mihelich, B. L. et al. miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J. Biol. Chem. 286, 44503-44511 (2011).
28. Hirata, H. et al. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One 8, e55502 (2013).
29. Liu, R., Li, J., Teng, Z., Zhang, Z. & Xu, Y. Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). PLoS One 8, e68982 (2013).
30. Qu, Y. et al. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int. J. Cancer 133, 544-555 (2013).
31. Appelhoff, R. J. et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxiainducible factor. J. Biol. Chem. 279, 38458-38465 (2004).
32. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25 (1997).
33. Zundel, W. et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396 (2000).
34. Zhong, H. et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545 (2000).
35. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 (2003).
36. Segura, M. F. et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. USA. 106, 1814-1819 (2009).
37. Hirata, H. et al. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One 7, e51056 (2012).
38. Lei, R. et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene 33, 1287-1296 (2014).
39. Zhang, D. et al. Thyroid hormone regulates muscle fiber type conversion via miR-133a1. J. Cell Biol. 207, 753-766 (2014).
40. Shi, Z. M. et al. MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One 7, e32709 (2012).
41. Sun, H. et al. TRAF6 upregulates expression of HIF-1alpha and promotes tumor angiogenesis. Cancer Res. 73, 4950-4959 (2013).